Virax Biolabs Group annual operating cash flow
2021
2022
2023
2024
2025
2026
Virax Biolabs Group Operating Cash Flow Growth & History (VRAX)
Virax Biolabs Group's operating cash flow was −$4.6M for fiscal 2026.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$4.6M | −$58,316 | — |
| 2025 | 2025-03-31 | −$4.6M | $1.7M | — |
| 2024 | 2024-03-31 | −$6.2M | −$2.1M | — |
| 2023 | 2023-03-31 | −$4.2M | −$3.4M | — |
| 2022 | 2022-03-31 | −$809,070 | −$218,884 | — |
| 2021 | 2021-03-31 | −$590,186 | — | — |
Virax Biolabs Group operating cash flow trends
Over the last five fiscal years, Virax Biolabs Group's operating cash flow decreased from −$590,186 to −$4.6M, a change of −$4.0M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group source filings ↗